Stockholm aims at becoming one of the world’s top life science regions

Regional Chair for Finance, Irene Svenonius (M), believes that Stockholm can realise the goal of becoming one of the world’s top 5 regions in life science by 20...

Moberg och Karo i avtal om nagelsvampsbehandling – byter varumärkesnamn

Moberg Pharma har ingått ett licensavtal med Karo Healthcare om kommersialiseringen av nagelsvampsbehandlingen Terclara i Europa. Genom samarbetet får produkten...

Muterad fågelinfluensa i Finland

Fem farmer för pälsdjur i Finland har en muterad variant av fågelinfluensavirus.

New rules for diagnostic products, but who will certify them? “An extreme shortage area”

In less than two weeks, new and stricter EU rules will enter into force for thousands of products used in important diagnoses of, among other things, cancer and...

The Swedish Academy of Sciences: “We have too many researchers”

Sweden does not need more researchers, but it does need better ones. According to the Royal Swedish Academy of Sciences, funding should be distributed to favour excellence.

Mathias Uhlén’s protein atlas is recognised as a global resource

The Human Protein Atlas is the first database in Sweden to be designated a Global Core Biodata Resource. According to Mathias Uhlén, this is a quality hallmark ...

Nytt läkemedel mot fibromyalgi godkänt – första på 16 år

Amerikanska Tonix Pharma har fått FDA-godkännande för sitt läkemedel Tonmya för behandling av smärta relaterat till det kroniska tillståndet fibromyalgi. Läkeme...

List: The coolest names in biotech

Hairy beasts, volcanic material and space strolling stand out on a US list of the best biotech company names, and on a list of the coolest names for pharmaceuti...

ZEISS Quality Innovation Days

The leading digital event from April 15-19, 2024.

Sepsisbolag tar in kapital

Bioteknikbolaget Aptahem, som utvecklar en behandling mot sepsis, har beslutat om en företrädesemission som kan ge bolaget upp till 34,6 miljoner kronor.

Nytt varsel på BMS – ska spara 1,5 miljarder

Bristol Myers Squibb, BMS, varslar 195 anställda efter att läkemedelsbolaget genomför ytterligare ett besparingspaket.

Biotech-entreprenör och sci-fi-författare – ”För att koppla av började jag skriva”

Han har grundat Lundabolaget Iconovo, författat en trilogi sci-fi-deckare och drömmer om en Netflix-serie baserad på hans egna böcker. ”Det roligaste är att ta ...

Alzinova tar steg mot fas II-studie i USA

Biofarmabolaget Alzinova hoppas kunna inleda en fas II-studie med sin vaccinkandidat mot Alzheimers under andra halvåret 2025.

Combining two drug delivery strategies to improve bioavailability

Danish researchers hope to increase the bioavailability of low solubility drugs.

The physician at the tech giant: “Observations in the emergency room made my mind up”

When Nasim Farrokhnia was in third grade at school in Tehran, the capital of Iran, her father gave her a book about Marie Curie, which soon became her favourite...

Nytt blodprov för Alzheimers ska användas i primärvården

Den amerikanska läkemedelsmyndigheten FDA har godkänt Roches blodtest Elecsys för bedömning av tidig Alzheimers sjukdom. Testet är godkänt i EU sedan i juli.

”We need compatibility“

Penilla Gunther, founder of Fokus Patient and chair of the European Patient Safety Foundation, hopes that the forthcoming life science strategy will focus on ef...

Double up for Korbinian Löbmann

This year, Korbinian Löbmann will moderate the New Updates in Drug Formulation & Bioavailability meeting in Copenhagen for the fifth time. Furthermore, he will ...

Column: "Are we already living in the new normal?"

2020 felt like the year that we were building the house around us whilst moving into it at the same time.

Hello Jenni Nordborg!

Life Science Sweden would like to know more about Jenni Nordborg and asks her about her new job, why she became a chemical engineer and who her role model is.

Rising interest in CRISPR treatments

Treatments using CRISPR technology are emerging as one of the hottest medical trends in the United States – and the FDA is doing its best to promote the development.

PharmaSurgics in Sweden AB

EMA-granskning bekräftar risk för ny cancer efter CAR-T

CAR-T-terapier mot cancer kan i sällsynta fall ge upphov till sekundära cancersjukdomar. Det slås nu fast av den europeiska läkemedelsmyndigheten EMA, som kräve...

Editorial: ”AI that both impresses and frightens”

”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...